MAWDBP1 Activators
MAWDBP1 Activators are a series of chemical compounds that enhance the functional activity of MAWDBP1 by primarily targeting the TGF-beta signaling pathway, in which MAWDBP1 plays a negative regulatory role. Compounds like Resveratrol, Pirfenidone, and Tranilast, known for their modulatory effects on sirtuin activity and anti-fibrotic properties, respectively, contribute to reducing TGF-beta pathway activity. This reduction indirectly amplifies MAWDBP1's negative regulation of this pathway, thereby enhancing its functional role. Similarly, inhibitors like SB-431542, LY364947, Galunisertib, A-83-01, Nintedanib, Halofuginone, RepSox, GW788388, and SD-208, which target the TGF-beta receptor or its kinases, also facilitate the enhanced activity of MAWDBP1. By inhibiting TGF-beta receptor kinases, these compounds create a biochemical environment conducive to MAWDBP1's activity, emphasizing its role in the negative regulation of TGF-beta signaling, crucial for the maintenance of gastrointestinal epithelium and other related functions.
In the cytoplasm, where MAWDBP1 is predominantly active, the indirect influence of these activators on TGF-beta signaling plays a pivotal role in dictating its functional efficacy. The diverse nature of these compounds, ranging from tyrosine kinase inhibitors like Nintedanib to specific TGF-beta pathway inhibitors like Halofuginone and SD-208, points to a multifaceted approach in enhancing MAWDBP1 activity. Each activator, though varied in its primary mechanism, converges on a common pathway, thereby potentiating MAWDBP1's role in negative regulation. This concerted action ensures that the pathways antagonized by MAWDBP1, such as the negative regulation of SMAD protein signal transduction and the transforming growth factor beta receptor signaling pathway, are effectively downregulated. As a result, MAWDBP1's activity in these pathways is not just preserved but significantly enhanced, underscoring the intricate network of cellular signaling that governs its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol, through its ability to modulate sirtuin activity, indirectly enhances the activity of MAWDBP1. Sirtuins influence TGF-beta signaling, which MAWDBP1 negatively regulates. Thus, resveratrol's action leads to a reduction in TGF-beta signaling, indirectly enhancing MAWDBP1's negative regulatory role. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is an inhibitor of the TGF-beta receptor. By inhibiting this receptor, it aids in the negative regulation of the TGF-beta signaling pathway, a process in which MAWDBP1 is involved. This results in enhanced activity of MAWDBP1 in its role of negatively regulating this pathway. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947, a TGF-beta receptor kinase inhibitor, indirectly enhances MAWDBP1 activity by inhibiting TGF-beta signaling. As MAWDBP1 negatively regulates this pathway, the inhibition by LY364947 supports MAWDBP1’s functional role. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299, a TGF-beta receptor kinase inhibitor, helps in reducing TGF-beta signaling. This reduction in pathway activity indirectly boosts the negative regulatory role of MAWDBP1 in this pathway. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01, by inhibiting ALK5, ALK7, and TGF-beta receptor I kinases, reduces TGF-beta signaling. This action indirectly supports the activity of MAWDBP1, which is involved in negatively regulating the TGF-beta pathway. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
Pirfenidone has anti-fibrotic properties and modulates TGF-beta signaling. By reducing TGF-beta activity, it supports MAWDBP1's role in negatively regulating this pathway, thereby indirectly enhancing its activity. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $31.00 $103.00 $283.00 $978.00 | 2 | |
Tranilast, known for its anti-inflammatory and anti-fibrotic effects, reduces TGF-beta signaling. This action indirectly supports MAWDBP1's negative regulatory role in the TGF-beta pathway. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib, a tyrosine kinase inhibitor, indirectly impacts TGF-beta signaling pathways. By doing so, it aids in the enhancement of MAWDBP1's activity in negatively regulating these pathways. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
Halofuginone inhibits TGF-beta signaling through Smad3 phosphorylation inhibition. This inhibition aids in enhancing MAWDBP1's role in the negative regulation of the TGF-beta signaling pathway. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox is an inhibitor of the TGF-beta type I receptor ALK5. By inhibiting ALK5, RepSox indirectly boosts MAWDBP1's activity by reducing TGF-beta signaling, which MAWDBP1 negatively regulates. | ||||||